Prosecution Insights
Last updated: November 04, 2026
Application No. 17/639,023

METHOD AND DEVICE FOR PATHOGEN OR ANTIBODY DETECTION USING UNMODIFIED SIGNALING SUBSTANCES WITH OR WITHOUT UNLABELED DETECTION REAGENTS

Final Rejection
Filed
Feb 28, 2022
Priority
Aug 27, 2019 — provisional 62/892,258 +1 more
Examiner
ALLEN, MICHAEL D
Art Unit
1671
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nano Discovery Inc.
OA Round
2 (Final)
32%
Grant Probability
At Risk
3-4
OA Rounds
0m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants only 32% of cases
32%
Career Allowance Rate
159 granted / 500 resolved
-28.2% vs TC avg
Strong +49% interview lift
Without
With
+48.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
73 currently pending
Career history
572
Total Applications
across all art units

Statute-Specific Performance

§101
9.1%
-30.9% vs TC avg
§103
20.7%
-19.3% vs TC avg
§102
10.9%
-29.1% vs TC avg
§112
43.3%
+3.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 500 resolved cases

Prosecution Timeline

Feb 28, 2022
Application Filed
Jan 23, 2026
Non-Final Rejection (signed)
Feb 26, 2026
Non-Final Rejection mailed
May 26, 2026
Response Filed
Aug 17, 2026
Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12606831
METHOD FOR PRODUCING T CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR
5y 5m to grant Granted Apr 21, 2026
Patent 12527867
USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
2y 8m to grant Granted Jan 20, 2026
Patent 12486326
ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
2y 5m to grant Granted Dec 02, 2025
Patent 12473373
BISPECIFIC ANTIBODY MOLECULES BINDING TO CD3 AND EGFRvIII
2y 2m to grant Granted Nov 18, 2025
Patent 12447195
ENGINEERED SIRPa VARIANTS AND METHODS OF USE THEREOF
1y 11m to grant Granted Oct 21, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
32%
Grant Probability
80%
With Interview (+48.7%)
3y 8m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 500 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month